Table 1. Pharmacokinetic/pharmacodynamic study design of pozelimab and cemdisiran combination in male cynomolgus monkeys.
| Group | Animals, n | Agent* | Dose day | Dose route | Dose level (mg/kg) | Dose concentration (mg/mL) |
|---|---|---|---|---|---|---|
| 1 | 3 | Cemdisiran | 1 | SC | 5 | 5 |
| 2 | 3 | Cemdisiran | 1 | 25 | 25 | |
| 3 | 4 | Pozelimab | 1 | 5 | 5 | |
| 4 | 4 | Pozelimab | 1 | 10 | 10 | |
| 5 | 5 | Cemdisiran + pozelimab |
1 15 |
5 5 |
5 5 |
|
| 6 | 5 | Cemdisiran + pozelimab |
1 15 |
5 10 |
5 10 |
|
| 7 | 5 | Cemdisiran + pozelimab |
1 15 |
25 10 |
25 10 |
SC, subcutaneous.
*Administered as a single SC injection.